Incorporating New Therapeutic Strategies in the Treatment of Hodgkin Lymphoma

Download All
In this online educational program, expert faculty explore optimal care for patients with Hodgkin lymphoma including risk-adapted and response-adapted therapeutic strategies, management of both early and late disease relapse, treatment of progressive disease post transplantation, considerations for elderly patients, and emerging treatment approaches.

Downloadable Slidesets

In this downloadable slideset, Ranjana Advani, MD, provides an overview of Hodgkin lymphoma epidemiology, current prognostic risk factors used in clinic, and emerging biomarkers for risk assessment in patients with this disease.

Released: December 12, 2017

In this downloadable slideset, Ranjana Advani, MD, reviews available evidence regarding the initial treatment of patients diagnosed with classical Hodgkin lymphoma.

Released: December 13, 2017

In this downloadable slideset, Robert W. Chen, MD, presents current evidence supporting the management of HL in transplantation-eligible patients.

Released: December 14, 2017

In this downloadable slideset, Pier Luigi Zinzani, MD, PhD, reviews current and emerging data relevant to the treatment of patients with primary refractory classical Hodgkin lymphoma.

Released: December 12, 2017

In this downloadable slideset, Andrew M. Evens, DO, MSc, FACP, discusses current evidence for the management of HL in patients aged 60 years and older.

Released: December 12, 2017

In this downloadable slideset, Pier Luigi Zinzani, MD, PhD, reviews current and emerging data relevant to the treatment of patients with classical Hodgkin lymphoma and progression following stem cell transplantation.

Released: December 12, 2017
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Merck & Co., Inc.
Takeda Oncology
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings